PRIME: priority medicines

What is the PRIME scheme?

The PRIME (Priority Medicines) scheme is a regulatory support programme established by the European Medicines Agency (EMA). It is designed to enhance support for the development of medicines that target an unmet medical need, by providing early and intensified interaction with developers, so that promising therapies can reach patients more quickly. European Medicines Agency (EMA)
In effect, PRIME builds on the existing regulatory framework — scientific advice, accelerated assessment, etc. — and adds tailored early-dialogue, development support and prioritised assessment for medicines that meet the eligibility criteria. European Medicines Agency (EMA)+1

---

Why does PRIME exist? — the rationale

There are several interconnected reasons why the EMA created the PRIME scheme:

1. Addressing unmet medical needs
   Many conditions lack effective therapies, or new treatments could substantially improve outcomes (morbidity, mortality, quality of life). PRIME specifically targets medicines that either fill a therapeutic gap or offer a major therapeutic advantage over existing treatments. European Medicines Agency (EMA)+1
2. Enabling earlier patient access
   By engaging early with developers (during development rather than waiting until a marketing-authorisation application), EMA aims to optimise the development plan and reduce avoidable delays. The better-designed the evidence package, the faster the assessment and the earlier patients might benefit. European Medicines Agency (EMA)
3. Improving development efficiency and data quality
   When regulators enter the picture early, they can help shape development plans (clinical trials, manufacturing, quality data packages) so that the ensuing dossier is more robust and more aligned with expectations. This reduces back-and-forth, rework, wasted resources. For sponsors especially smaller ones, this is valuable. European Medicines Agency (EMA)+1
4. Stimulating innovation
   The scheme encourages development in challenging therapeutic areas (rare diseases, oncology, neurology, infectious diseases) where the standard path might be long and risky. The additional regulatory support is an incentive.
5. Harmonising regulatory pathways and efficiency across the EU
   The scheme reinforces the EU’s regulatory network, helps converge expectations, provides clarity for industry, and links early-dialogue to later assessment. Additionally, PRIME interacts with other tools (accelerated assessment) to streamline the path. European Medicines Agency (EMA)

---

Eligibility & operation: what MAHs / developers need to know

If you’re a marketing-authorisation holder (MAH) or a development sponsor, and you’re targeting the EU market, these are the key aspects of PRIME you should understand.

Eligibility criteria

• The medicine must be not yet authorised in the EU and target a condition with an unmet medical need: either no authorised treatment option exists, or the new medicine offers a major therapeutic advantage. European Medicines Agency (EMA)
• The applicant must provide preliminary clinical evidence or proof of concept that the medicine has promising activity (for example from early trials or strong non-clinical models) showing meaningful improvement—impacting prevention, onset, duration of disease, or improving morbidity/mortality. European Medicines Agency (EMA)
• The scheme is voluntary and early in development: entry is typically during exploratory clinical trial phases. For SMEs or academics, there is an “Early Entry” version of PRIME when proof-of-principle is demonstrated. European Medicines Agency (EMA)

When and how to apply

• Application is via the EMA’s IRIS platform: the applicant registers and submits a justification template, along with supporting data, via the secure online platform. European Medicines Agency (EMA)
• It is ideal to apply early in development—before the marketing-authorisation stage—to maximise benefit and influence development plans. European Medicines Agency (EMA)

What support does PRIME give?

Once a product is accepted into PRIME, the following key benefits materialise:

• Early appointment of a rapporteur from the relevant EMA Committee (Committee for Medicinal Products for Human Use—CHMP—or CAT for advanced therapies) to provide preparatory discussions. European Medicines Agency (EMA)
• Kick-off meeting with expert multidisciplinary group from EMA and the European medicines regulatory network to review development strategy, regulatory pathway, key issues. European Medicines Agency (EMA)
• Dedicated EMA scientific coordinator to serve as contact point for all PRIME-related support. European Medicines Agency (EMA)
• Iterative scientific advice at major milestones, engagement of other stakeholders (HTA bodies, patients) and possibly shortened timelines for advice. European Medicines Agency (EMA)
• Submission-readiness meeting ahead of the marketing-authorisation application to assess dossier maturity, post-marketing plans, regulatory challenges. European Medicines Agency (EMA)
• Potential eligibility for accelerated assessment when submitting for marketing authorisation. European Medicines Agency (EMA)

Things to consider / risks

• Entry into PRIME does not guarantee approval—it is support not a shortcut past scientific/regulatory rigour.
• The preparatory work (quality, manufacturing, clinical data) still needs to be robust; the PRIME scheme emphasises “early dialogue to optimise development” not lowering standards. European Medicines Agency (EMA)
• Timing is important: applying too late in development reduces ability to influence the plan; applying too early without sufficient proof of concept may lead to denial. For example, the five-year review showed many applications denied (68% denied by Sept 2025) pointing to the need for convincing data. European Medicines Agency (EMA)
• SMEs/academia may have additional considerations: PRIME offers fee exemptions for scientific advice and special support, but resource limitations (clinical trial funding, manufacturing scale-up) still apply. European Medicines Agency (EMA)
• Regulatory strategy needs to be well aligned with commercial and development strategy: engaging with EMA, planning HTA/market access implications early, manufacturing/quality readiness, lifecycle planning.

---

Why this matters for your industry / for you as a consultant

Since you provide consulting services (regulatory affairs, pharmacovigilance, clinical documentation) and have a medical-store business background, here’s how you can leverage this:

• For clients developing new medicines (or biotech start-ups) targeting the EU market, understanding and advising on PRIME eligibility and strategy is a high-value service: you can guide them on when to apply, how to structure early clinical/non-clinical data, how to plan manufacturing and quality data with the knowledge that they may benefit from PRIME support.
• Early regulatory strategy is closely tied to later lifecycle management and pharmacovigilance obligations: a product guided from early development via PRIME may have stronger planning for safety monitoring, post-marketing commitments, HTA/market access alignment.
• For your consulting documentation and regulatory operations services: you can incorporate PRIME-specific checklists (e.g., proof of concept evidence, unmet need justification, regulatory roadmap, engagement plan with EMA, dossier readiness meeting) as part of your standard offering.
• Even for the medical-store business side: while this is upstream drug development and not retail pharmacy, having strong knowledge of innovation pathways (like PRIME) helps you stay connected with pipeline medicines, future therapies, market trends — which can inform store stocking strategy, patient counselling, educational outreach.

---

Summary

The PRIME scheme is a forward-looking regulatory instrument by the EMA designed to accelerate patient access to therapies that meet high unmet needs. For MAHs and developers it offers clear benefits—early regulatory engagement, structured support, expedited evaluation—but also demands high quality, timely strategy and evidence generation. For regulatory affairs professionals and consultants, PRIME represents a key strategic checkpoint in development-planning and regulatory-pathway design.